Lyme and Infection Control with ACS 200

[Originally posted to FACT forum on Wed May 27, 2009 11:51 am]

Lyme seems suddenly to be everywhere and now we learn that most of us have Cytomegalic Virus too. This new research helps explain the sudden increase in Lyme world wide!

This information combined with the CMV research should be enough that, when considered altogether, leads me to believe that soon infections might overtake all other challenges including toxins, heavy metals, food sensitivities etcetera, as the key missing culprit that must be dealt with in all chronic disease patients if you are to see real lasting results!

INFECTION CONTROL- with ACS 200

ACS 200 becomes increasingly important since not too many will follow for any length of time the other suggestions for controlling chronic infections that I have made such as higher doses of BIOE’NR-G’Y C, which virtually anyone can handle in 8 gm a day or higher levels. Use C Stix to involve patients in the benefits of Vitamin C rich urine, as proof of ongoing detoxification effects. Also recommended are Immuni-T 2 or Vit D or Kyolic or short term use of high dose Vitamin A.

Most U.S. based patients have difficulty locating doctors offering IV UVB and Ozone. That is sad since it provides a great way to start any treatment to lower total body burden of all Pathogens. As an alternative, patients can use ACS very aggressively for a time. Start with 1 ounce and then use 1-2 ounces a day of ACS 200, as a part of their infection control program until results are being seen, usually 2-4 weeks minimum. Then lower the ACS dose to save money, BUT DO NOT STOP TAKING ACS 200, using at least doses of 30 sprays tid-qid for several months or even years along with my other suggestions.

Then follow my FIGHT program so that their own body over time can help control their total body burden of these newly recognized pathogens that clearly none of us can avoid. Read Plague Times by Ewald and get the full story on infections!

Garry F. Gordon MD,DO,MD(H)
President, Gordon Research Institute
www.gordonresearch.com

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Discovery Of Lyme Disease Bug Clone May Explain Disease Spread
ScienceDaily (June 29, 2008)
http://www.sciencedaily.com/releases/2008/06/080626145806.htm

Benjamin Luft, M.D., Professor of Medicine, Stony Brook University Medical Center, and colleagues discovered that a certain clone of Borrelia burgdorferi, the spirochete that causes Lyme disease, appears to be the most common strain causing Lyme disease in North America and Europe, and may account for the increase in cases for the past 20 years.
According to Dr. Luft, Lyme disease is the most common vector-borne disease in the United States with more than 20,000 cases reported annually. While B. burgdorferi is the primary pathogen in the United States, clones of the pathogen are known to cause major disease. The ospC-A clone was one of the first strains ever identified.
In a new article, Dr. Luft and colleagues detail various methods of genetic testing of 68 B. burgdorferi isolates from Europe and North America. Based on the findings of their tests, the researchers concluded that the ospC-A clone dispersed rapidly and widely in the recent past and in both regions of the world.
“I believe this discovery will make an important contribution since it identifies an identical and high virulence clone of Borrelia in both Europe and North America,” said Dr. Luft. “This may explain the recent spread of Lyme disease in North America.”
The researchers report that the isolates of the clone were prevalent on both continents and uniform in DNA sequences, which suggests a recent trans-oceanic migration. More specifically, they explained: “The European and North American Populations of B. burgdorferi sensu stricto have diverged significantly because of genetic drift. Plasmid genes evolved independently and showed various effects of adaptive divergence and diversifying selection…genetic variation within the two continents contributed to most of the total sequence diversity, which suggests recent common ancestry, migration, or both, between the European and North American populations.”
The research was funded partly by the Lyme Disease Association and the National Institutes of Health. Dr. Luft’s colleagues include: Wei-Gang Qui, Ph.D., and William D. McCaig, Hunter College of the City University of New York; John F. Bruno and Yun Xu of Stony Brook University; Ian Livey, Baxter Vaccine AG, Orth/Donau, Austria, and Martin M. Schriefer, of the Centers of Disease Control and Prevention, Fort Collins, Colorado.
________________________________________
Journal reference:
1. . Wide Distribution of a High-Virulence Borrelia burgdorferi Clone in Europe and North America. Emerging Infectious Diseases, July 2008
Adapted from materials provided by Stony Brook University Medical Center.